Login
$CTNM
$9.67 -$0.19 (1.93%) Live

Company Executives

Officer Age In this role 2025 pay Source
Carmine N. Stengone
President, Chief Executive Officer and Director
50 Since 2018
8 years
$3,409,448
Peter T. Slover
Chief Financial Officer
51 Since 2020
6 years
$1,577,903
Daniel S. Lorrain
Chief Scientific Officer
57 Since 2018
8 years
Not reported
John S. Healy
General Counsel and Corporate Secretary
54 Not stated Not reported
Timothy R. Watkins
CMO & Head of Development
Title from the Form 4 dated Jun 30, 2026
52 Not stated $1,763,323

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
3
serving now
Independent
1 of 3
stated in the proxy
Director Independent 2025 pay Source
Lori M. Lyons-Williams
Independent $96,535
Diego Miralles
Not independent $254,156
Stengone
Not independent Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

JJDC
holder of more than 5% of our outstanding common stock at the time of the IPO
$ 5,000,000

Purchased shares of Class A common stock in our IPO at $16.00 per share (312,500 shares).

Entities affiliated with Franklin Advisers, Inc.
holder of more than 5% of our outstanding common stock at the time of the IPO
$ 10,000,000

Purchased shares of Class A common stock in our IPO at $16.00 per share (625,000 shares).

Entities affiliated with Sectoral Asset Management Inc.
holder of more than 5% of our outstanding common stock at the time of the IPO; Stefan Larson, a former director, is a partner of Sectoral Asset Management
$ 2,000,000

Purchased shares of Class A common stock in our IPO at $16.00 per share (125,000 shares).

Entities affiliated with Suvretta Capital Management, LLC
holder of more than 5% of our outstanding common stock at the time of the IPO
$ 24,000,000

Purchased shares of Class A common stock in our IPO at $16.00 per share (1,500,000 shares).

Entities affiliated with Perceptive Life Sciences Master Fund, Ltd.
holder of more than 5% of our outstanding common stock at the time of the IPO
$ 14,400,000

Purchased shares of Class A common stock in our IPO at $16.00 per share (900,000 shares).

Versant Ventures; Baker Brothers; Sectoral Asset Management Inc.; Suvretta Capital Management, LLC; Franklin Advisers, Inc.; Perceptive Life Sciences Master Fund, Ltd.; JJDC
holders of our capital stock; Versant Ventures and Baker Brothers were 5% or greater holders of our voting securities at the time of entering the agreement
Amount not stated

Amended and restated Investors' Rights Agreement granting certain holders registration rights.

Janssen Pharmaceutica NV, a Johnson & Johnson company (J&J)
$50.0 million
February 2023

Exclusive worldwide license of PIPE-307 granted to J&J; we received an upfront payment.

With Janssen Pharmaceutica NV Open in proxy
Kym Lorrain
wife of Dr. Daniel Lorrain, our Chief Scientific Officer
Amount not stated
currently employed

Employed as an Associate Director; compensation comparable to similarly situated employees and approved by the compensation committee.

John S. Healy
consultant under a legal consulting agreement; joined the Company as General Counsel & Corporate Secretary in June 2024
Amount not stated
April 2022 to June 3, 2024

Legal consulting agreement with monthly retainer, later increased; terminated June 3, 2024.

Diego Miralles, M.D.
advisor under advisor agreement; joined the Board effective March 2025
Amount not stated
June 2024 to March 14, 2025

Strategic, scientific and clinical consulting advisor agreement with monthly retainer, reduced later; option for 5,000 shares granted June 2024; terminated March 14, 2025.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support